Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Boehringer Ingelheim
Johnson and Johnson
McKinsey
Medtronic

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SELEGILINE HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Selegiline Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000188 Selegiline in Treatment of Cocaine Dependence - 2 Completed National Institute on Drug Abuse (NIDA) Phase 2 1994-09-01 The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.
NCT00000188 Selegiline in Treatment of Cocaine Dependence - 2 Completed University of Pennsylvania Phase 2 1994-09-01 The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.
NCT00000201 Pharmacological Modulation of Cocaine Effects - 1 Completed Johns Hopkins University Phase 2 1969-12-31 The purpose of this study is to conduct human laboratory studies of possible cocaine interactions with various potential treatment medications.
NCT00000201 Pharmacological Modulation of Cocaine Effects - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1969-12-31 The purpose of this study is to conduct human laboratory studies of possible cocaine interactions with various potential treatment medications.
NCT00000336 Selegiline in Outpatient Treatment for Cocaine Dependence - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1995-01-01 The purpose of this study is to evaluate the efficacy and clinical safety of selegiline in the treatment of cocaine dependence and to assess neurotoxicity (Magnetic Resonance Imaging, MRI) post-hoc as a possible variable for future stratification in clinical trials.
NCT00000337 Infusion Laboratory: Protocol 1 - Selegeline - 2 Completed National Institute on Drug Abuse (NIDA) Phase 1 1994-11-01 The purpose of this study is to determine the effects of selegiline on the subjective and physiological effects of cocaine challenge in chronic crack abusers, and to evaluate clinical safety issues pertaining to selegeline, to cocaine and their interaction in a chronic crack dependent population.
NCT00002154 A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia Completed The Dana Foundation Phase 2 1969-12-31 The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who have mild to moderate dementia (a decline in their mental abilities).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Selegiline Hydrochloride

Condition Name

Condition Name for Selegiline Hydrochloride
Intervention Trials
Parkinson's Disease 6
Cocaine-Related Disorders 5
HIV Infections 3
Parkinson Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Selegiline Hydrochloride
Intervention Trials
Parkinson Disease 10
Cocaine-Related Disorders 5
HIV Infections 4
Cognition Disorders 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Selegiline Hydrochloride

Trials by Country

Trials by Country for Selegiline Hydrochloride
Location Trials
United States 114
Iran, Islamic Republic of 1
Canada 1
Germany 1
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Selegiline Hydrochloride
Location Trials
California 14
Maryland 12
Florida 7
Texas 6
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Selegiline Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Selegiline Hydrochloride
Clinical Trial Phase Trials
Phase 4 10
Phase 3 3
Phase 2 15
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Selegiline Hydrochloride
Clinical Trial Phase Trials
Completed 28
Terminated 2
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Selegiline Hydrochloride

Sponsor Name

Sponsor Name for Selegiline Hydrochloride
Sponsor Trials
National Institute on Drug Abuse (NIDA) 11
National Institute of Neurological Disorders and Stroke (NINDS) 6
Somerset Pharmaceuticals 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Selegiline Hydrochloride
Sponsor Trials
Other 20
NIH 19
Industry 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
AstraZeneca
Johnson and Johnson
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.